| Title |
Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, October 2016
|
| DOI | 10.1007/s00262-016-1918-2 |
| Pubmed ID | |
| Authors |
Taofeek K. Owonikoko, Mukesh Kumar, Shu Yang, Alice O. Kamphorst, Rathi N. Pillai, Rama Akondy, Vivek Nautiyal, Monica S. Chatwal, Wendy M. Book, Anurag Sahu, Gabriel L. Sica, Rafi Ahmed, Suresh S. Ramalingam |
| Abstract |
The increased availability of immunotherapeutic agents for the treatment of a wide array of cancer in the general oncology practice setting will reveal rare and unique toxicities. The mechanism of cardiac allograft rejection in the context of PD-1 antibody therapy was explored in a patient with cutaneous squamous cell cancer complicating long-standing cardiac allograft. Immune cell infiltrate in the myocardium and peripheral blood lymphocyte repertoire were assessed using myocardial biopsy and temporal analysis of peripheral blood samples. The efficacy of high-intensity immunosuppression to reverse graft rejection was explored. Endomyocardial biopsy showed acute moderate diffuse cellular rejection with a predominant population of CD3+, CD8+ and CD4+ infiltrating lymphocytes; peripheral blood circulating lymphocytes showed a high frequency of proliferating and activated CD8+ T cells expressing PD-1 compared to a normal control. There was no difference in the activation and proliferation of CD4+ T cells compared to a normal control. Cardiac function improved following high-intensity immunosuppression and patient survived for up to 7 months after discontinuation of nivolumab. Immune checkpoint inhibitors should be avoided in allograft recipients but high-intensity immunosuppression is effective to salvage allograft rejection induced by these agents. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Egypt | 1 | 2% |
| Unknown | 45 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 15% |
| Researcher | 6 | 13% |
| Student > Doctoral Student | 4 | 9% |
| Student > Ph. D. Student | 4 | 9% |
| Student > Bachelor | 3 | 7% |
| Other | 10 | 22% |
| Unknown | 12 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 46% |
| Immunology and Microbiology | 4 | 9% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Nursing and Health Professions | 2 | 4% |
| Agricultural and Biological Sciences | 2 | 4% |
| Other | 0 | 0% |
| Unknown | 14 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 September 2017.
All research outputs
#14,869,124
of 22,899,952 outputs
Outputs from Cancer Immunology, Immunotherapy
#2,063
of 2,888 outputs
Outputs of similar age
#189,116
of 315,621 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#17
of 32 outputs
Altmetric has tracked 22,899,952 research outputs across all sources so far. This one is in the 33rd percentile – i.e., 33% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,888 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,621 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.